EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice

Martha M O'Kennedy iD, Robyn Roth, Karen Ebersohn, Lissinda H du Plessis iD, Sipho Mamputha, Daria A Rutkowska, Ilse du Preez, Jan A Verschoor, Yolandy Lemmer

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0301340 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Martha M O'Kennedy und 8 weiteren Autor:innen. Beteiligte Einrichtung: Council for Scientific and Industrial Research (CSIR), Chemical Cluster, Pretoria, South Africa. Hauptthemen laut MEDLINE: African Horse Sickness Virus, African Horse Sickness, Viral Vaccines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horserace Betting Levy Board, Council for Scientific and Industrial Research, South Africa.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A safe, highly immunogenic multivalent vaccine to protect against all nine serotypes of African horse sickness virus (AHSV), will revolutionise the AHS vaccine industry in endemic countries and beyond. Plant-produced AHS virus-like particles (VLPs) and soluble viral protein 2 (VP2) vaccine candidates were developed that have the potential to protect against all nine serotypes but can equally well be formulated as mono- and bi-valent formulations for localised outbreaks of specific serotypes. In the first interferon α/β receptor knock-out (IFNAR -/- ) mice trial conducted, a nine-serotype (nonavalent) vaccine administered as two pentavalent (5 μg per serotype) vaccines (VLP/VP2 combination or exclusively VP2), were directly compared to the commercially available AHS live attenuated vaccine. In a follow up trial, mice were vaccinated with an adjuvanted nine-serotype multivalent VP2 vaccine in a prime boost strategy and resulted in the desired neutralising antibody titres of 1:320, previously demonstrated to confer protective immunity in IFNAR -/- mice. In addition, the plant-produced VP2 vaccine performed favourably when compared to the commercial vaccine. Here we provide compelling data for a nonavalent VP2-based vaccine candidate, with the VP2 from each serotype being antigenically distinguishable based on LC-MS/MS and ELISA data. This is the first preclinical trial demonstrating the ability of an adjuvanted nonavalent cocktail of soluble, plant-expressed AHS VP2 proteins administered in a prime-boost strategy eliciting high antibody titres against all 9 AHSV serotypes. Furthermore, elevated T helper cells 2 (T h 2) and T h 1, indicative of humoral and cell-mediated memory T cell immune responses, respectively, were detected in mouse serum collected 14 days after the multivalent prime-boost vaccination. Both T h 2 and T h 1 may play a role to confer protective immunity. These preclinical immunogenicity studies paved the way to test the safety and protective efficacy of the plant-produced nonavalent VP2 vaccine candidate in the target animals, horses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

African Horse Sickness VirusAfrican Horse SicknessViral VaccinesAnimalsMiceHorsesVaccines, CombinedChromatography, LiquidCapsid ProteinsTandem Mass SpectrometryAntibodies, Viral

Substanzen

Vaccines, CombinedCapsid ProteinsViral VaccinesAntibodies, Viral

Autor:innen und Institutionen

  • Council for Scientific and Industrial Research (CSIR), Chemical Cluster, Pretoria, South Africa.
  • Department of Veterinary Tropical Diseases, University of Pretoria, Pretoria, South Africa.
  • Centre of Excellence for Pharmaceutical Sciences (PharmacenTM), North-West University, Potchefstroom, South Africa.
  • Department of Biochemistry, University of Pretoria, Pretoria, South Africa.

ORCID-Profile: Martha M O'Kennedy, Lissinda H du Plessis

Förderung

  • Horserace Betting Levy Board
  • Council for Scientific and Industrial Research, South Africa

Zitieren

APA

O'Kennedy, M. M., Roth, R., Ebersohn, K., du Plessis, L. H., Mamputha, S., Rutkowska, D. A., du Preez, I., Verschoor, J. A., & Lemmer, Y. (2024). Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice. PLOS ONE. https://doi.org/10.1371/journal.pone.0301340

Vancouver

O'Kennedy MM, Roth R, Ebersohn K, du Plessis LH, Mamputha S, Rutkowska DA, et al. Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice. PLOS ONE. 2024. doi:10.1371/journal.pone.0301340

BibTeX
@article{OKennedy2024,
  author = {O'Kennedy, Martha M and Roth, Robyn and Ebersohn, Karen and du Plessis, Lissinda H and Mamputha, Sipho and Rutkowska, Daria A and du Preez, Ilse and Verschoor, Jan A and Lemmer, Yolandy},
  title = {Immunogenic profile of a plant-produced nonavalent African horse sickness viral protein 2 (VP2) vaccine in IFNAR-/- mice},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0301340}
}
Kostenlos starten →